Article date: February 2018
By: Caroline Solas, Sylvie Bregigeon, Olivia Faucher‐Zaegel, Sylvie Quaranta, Véronique Obry‐Roguet, Catherine Tamalet, Bruno Lacarelle, Isabelle Poizot‐Martin in Volume 84, Issue 2, pages 404-409
We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration and estimated glomerular renal function in human immunodeficiency virus–hepatitis C virus coinfected patients receiving a tenofovir‐based antiretroviral regimen and treated with ledipasvir/sofosbuvir. Twenty‐six patients [81% male, median age: 51 years; hepatitis C virus genotype 1(75%)/4(15%)] were included. Tenofovir trough concentration (interquartile range) increased from 78 ng ml–1 (53–110) at baseline to 141 ng ml–1 (72–176) at 1 month (P = 0.003). No significant difference on estimated glomerular renal function using both Cockroft–Gault and Modification of Diet in Renal Disease formulae, respectively, [median (interquartile range)] was observed between baseline [101.3 ml min–1 (91.1–114.1); 95.6 ml min–1 (86.5–111.2)], 1 month [102.4 ml min–1 (89.8–112.9), P = 0.26; 92.5 ml min–1 (88.1–114.3), P = 0.27], end‐of‐treatment [96.5 ml min–1 (82.4–115.4), P = 0.39; 95.4 ml min–1 (84.2–105.4), P = 0.16] and 12 weeks after the end of treatment [100.5 ml min–1 (83.3–111.9), P = 0.24; 93.4 ml min–1 (82.2–103.5), P = 0.16]. Three patients progressed from chronic kidney disease stage 1 to stage 2 at 12 weeks post‐treatment. A significant increase in tenofovir exposure through P‐glycoprotein inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment.
DOI: 10.1111/bcp.13450
View this article